Mankind Pharma is a renowned Indian pharmaceutical and healthcare products company, headquartered in Delhi. Since its inception in 1991, the company has rapidly grown to become a prominent player in the pharmaceutical industry, actively commencing its operations in 1995.
The company’s product portfolio covers a wide array of therapeutic areas. Mankind Pharma is committed to delivering high-quality and affordable healthcare solutions, aiming to improve the lives of millions worldwide.
This article aims to explore the share price target of Mankind Pharma from 2024 to 2030, as well as analyze the viability of Mankind Pharma as a promising stock to consider for investment.
MANKIND PHARMA Q3 Result Highlight
- Mankind Pharma’s Q3 net profit surged 55% year-on-year to Rs 460 crore.
- Revenue from operations rose to Rs 2,607 crore, a 25% increase compared to the year-ago period.
- Domestic business witnessed a robust 20% year-on-year growth, with revenue reaching Rs 2,400 crore.
- The company ranked 4th in the pharmaceutical market with a 4.5% market share and led in prescription sales with over 15.3% market share.
- Mankind Pharma’s top 5 therapeutics outperformed the market by 1.5 times, with increased market share in 18 out of the top 20 brands.
- Revenue from the consumer healthcare segment experienced a slight decline of 4.8% year-on-year, attributed to inventory optimization and implementation of IT tools.
HOW TO BUY MANKIND PHARMA SHARES ?
You can buy Mankind Pharma shares from the following trading platforms:
- Zerodha
- Upstox
- Groww
- AngleOne
- ICICIDirect
SHARE PRICE PREDICTION OF MANKIND PHARMA: 2024, 2025 to 2030
SHARE PRICE TARGET 2024 OF MANKIND PHARMA
| When | Maximum Price | Minimum Price |
| March 2024 | ₹2,176.90 | ₹1,892.96 |
| April 2024 | ₹2,113.50 | ₹1,837.82 |
| May 2024 | ₹2,082.26 | ₹1,810.66 |
| June 2024 | ₹2,157.22 | ₹1,875.85 |
| July 2024 | ₹2,135.65 | ₹1,857.09 |
| August 2024 | ₹2,221.08 | ₹1,931.37 |
| September 2024 | ₹2,309.92 | ₹2,008.63 |
| October 2024 | ₹2,264.63 | ₹1,969.24 |
| November 2024 | ₹2,332.57 | ₹2,028.32 |
| December 2024 | ₹2,390.88 | ₹2,079.03 |
In 2024, Mankind Pharma is expected to experience fluctuating prices, with the maximum and minimum prices varying from month to month. For instance, in March, the maximum price is projected to be ₹2,176.90, while the minimum price could be around ₹1,892.96. By December, both the maximum and minimum prices are anticipated to increase, potentially reaching ₹2,390.88 and ₹2,079.03, respectively, indicating a trend of growth and stability in the company’s market position.
SHARE PRICE TARGET 2025 OF MANKIND PHARMA
| When | Maximum Price | Minimum Price |
| January 2025 | ₹2,438.70 | ₹1,875.92 |
| February 2025 | ₹2,501.23 | ₹1,924.02 |
| March 2025 | ₹2,598.78 | ₹1,999.06 |
| April 2025 | ₹2,547.82 | ₹1,959.86 |
| May 2025 | ₹2,473.61 | ₹1,902.78 |
| June 2025 | ₹2,584.92 | ₹1,988.40 |
| July 2025 | ₹2,534.24 | ₹1,949.41 |
| August 2025 | ₹2,612.62 | ₹2,009.71 |
| September 2025 | ₹2,704.06 | ₹2,080.05 |
| October 2025 | ₹2,774.36 | ₹2,134.13 |
| November 2025 | ₹2,843.72 | ₹2,187.48 |
| December 2025 | ₹2,914.82 | ₹2,242.17 |
Throughout 2025, Mankind Pharma is expected to witness a steady increase in both its maximum and minimum prices. For instance, in January 2025, the maximum price is projected to reach ₹2,438.70, while the minimum price is anticipated to be around ₹1,875.92. This upward trend is anticipated to continue, with December 2025 seeing Mankind Pharma’s maximum and minimum prices projected to rise to ₹2,914.82 and ₹2,242.17, respectively. Investors and stakeholders may observe these developments closely to gauge the company’s performance and market dynamics.
MANKIND PHARMA SHARE PRICE PREDICTION 2026-2030
| Year | Maximum Price | Minimum Price |
| 2026 | ₹3200.98 | ₹1,629.90 |
| 2027 | ₹3987.78 | ₹1,385.42 |
| 2028 | ₹4567.50 | ₹2,493.75 |
| 2029 | ₹5439.93 | ₹2,122.55 |
| 2030 | ₹6123.52 | ₹5,704.66 |
In 2026, Mankind Pharma’s maximum share price is projected to reach ₹3,200.98, while the minimum price is anticipated to be around ₹1,629.90. Moving into 2027, the company’s share prices are expected to increase further, with a maximum price forecasted at ₹3,987.78 and a minimum price of ₹1,385.42. By 2028, Mankind Pharma is anticipated to experience significant growth, with the maximum share price reaching ₹4,567.50 and the minimum price projected to be ₹2,493.75.
As we progress into 2029, the upward trajectory is expected to persist, with the company’s maximum share price forecasted to reach ₹5,439.93 and the minimum price anticipated to be ₹2,122.55. By 2030, Mankind Pharma is projected to see its maximum share price surge to ₹6,123.52, while the minimum price is expected to increase substantially to ₹5,704.66. These predictions suggest a promising outlook for Mankind Pharma’s performance and market position in the coming years.
FINANCIAL CONDITION OF MANKIND PHARMA :LAST 5 YEARS
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
| Sales | 3,829 | 4,794 | 5,523 | 7,257 | 8,127 |
| Expenses | 3,124 | 3,550 | 4,151 | 5,457 | 6,430 |
| Operating Profit | 705 | 1,244 | 1,372 | 1,800 | 1,697 |
| OPM % | 18% | 26% | 25% | 25% | 21% |
| Other Income | 64 | 94 | 154 | 163 | 163 |
| Interest | 40 | 11 | 8 | 44 | 28 |
| Depreciation | 38 | 62 | 78 | 121 | 270 |
| Profit before tax | 691 | 1,265 | 1,440 | 1,798 | 1,563 |
| Tax % | 26% | 24% | 25% | 26% | 20% |
| Net Profit | 514 | 958 | 1,084 | 1,335 | 1,248 |
| EPS in Rs | 12.83 | 23.92 | 27.07 | 33.33 | 31.16 |
| Dividend Payout % | 0% | 32% | 0% | 0% | 0% |
The financial data for Mankind Pharma from March 2019 to March 2023 indicates a consistent growth trajectory with a few fluctuations in certain aspects. The Sales revenue steadily increased over the years, rising from ₹3,829 crores in March 2019 to ₹8,127 crores in March 2023. Similarly, the company’s Expenses also grew, reflecting the expansion of its operations and business activities.
Mankind Pharma’s Operating Profit (OP) witnessed steady growth, with the figures climbing from ₹705 crores in March 2019 to ₹1,697 crores in March 2023. The Operating Profit Margin (OPM %) experienced fluctuations, but it generally remained stable, ranging from 18% to 26%.
The Net Profit increased over the years, going from ₹514 crores in March 2019 to ₹1,248 crores in March 2023. However, there were fluctuations in the growth rate.
The Earnings Per Share (EPS) of Mankind Pharma showed steady growth, increasing from ₹12.83 in March 2019 to ₹31.16 in March 2023.
The Dividend Payout percentage remained at 0% during the entire period, indicating that the company did not distribute dividends to its shareholders during this time.
Overall, Mankind Pharma demonstrated consistent growth in its financial performance, with rising sales, operating profit, and net profit. While there were fluctuations in some aspects, the company maintained a strong position in the pharmaceutical industry and retained its focus on reinvesting profits for future growth and expansion rather than paying dividends to shareholders.
FAQS
COULD THE SHARE PRICE OF MANKIND PHARMA POTENTIALLY INCREASE IN 2024 ?
Yes, it is anticipated that Mankind Pharma share price will increase to ₹2,390.88 by the end of 2024.
WHAT HAS BEEN THE REVENUE GROWTH RATE OF MANKIND PHARMA OVER THE LAST FIVE YEARS?
The approximate average growth of Mankind Pharma over the last 5 years is around 28.17%.
WHAT IS THE PROJECTED SHARE PRICE TARGET OF MANKIND PHARMA FOR THE YEAR 2025?
Mankind pharma share price might reach around ₹2,914.82 by the end of 2025.
WHAT IS THE PROJECTED SHARE PRICE TARGET OF MANKIND PHARMA FOR THE YEAR 2030?
Mankind pharma share price might reach around ₹6123.52 by the end of 2030.
WHAT FACTORS OR DATA SERVE AS THE BASIS FOR PROJECTING THE TARGET SHARE PRICE FOR MANKIND PHARMA?
The projected target share price for Mankind Pharma is based on various factors, including the company’s financial performance, growth prospects, industry trends, and market sentiment.
Also Read:
- CG POWER AND INDUSTRIAL SOLUTIONS SHARE PRICE TARGET OF 2024,2025 TO 2030
- ZEE ENTERTAINMENT ENTERPRISES SHARE PRICE TARGET OF 2024,2025 TO 2030
- SUPREME INDUSTRIES SHARE PRICE TARGET OF 2024,2025 TO 2030
- JUST DIAL SHARE PRICE TARGET OF 2024,2025 TO 2030
CONCLUSION
The company’s sales revenue has steadily increased, demonstrating strong market demand for its pharmaceutical products. The operating profit margin remained stable, indicating effective cost management and operational efficiency.
Moreover, Mankind Pharma’s net profit has experienced substantial growth, which showcases the company’s ability to generate higher returns for its investors. The earnings per share (EPS) has also shown a positive trend, indicating that the company is generating greater profits for each outstanding share.
Overall, the data suggests that Mankind Pharma has been a promising investment option, given its consistent growth and financial performance over the last 5 years. However, as with any investment, it’s essential for investors to conduct thorough research and consider various factors before making any decisions. Factors such as the pharmaceutical industry’s regulatory environment, competition, and economic conditions should also be taken into account when assessing the potential growth and investment prospects of Mankind Pharma.
Leave a Reply